We are proud to present our 6th annual
Antibodies and Antibody Drug Conjugates conference on the 9th-10th of April 2018. The
Antibody-drug Conjugates market is expected to reach USD 30 Billion by 2023.
Antibodies and antibody drug conjugates (ADCs) have the potential to make a groundbreaking impact upon medicinal therapies, diagnostics and characterization of diseases. There is massive potential for
ADCs to be used in the development of targeted solid tumour therapies, due to their ability to act as precisely and effectively on target antigens.
Key topics that will be covered in the upcoming event include: fragment drug conjugates,
ADC payloads, site-selective
ADCs/ site-specific conjugation and the best linker and warhead combinations.
Benefits of Attending
- There have been massive strides within the field since the last event in 2016 - get the latest update on the progress being made and the developments within the ADC industry
- Presentations of clinical data from Phase I, II and III trials as case study examples of successes and short-falls of ADCs
- Hear about cutting edge combination therapies for onco-immunological therapies
- Evaluating the latest regulatory updates and how they might affect the industry
- Network with a range of industry and academic specialists and key vendors, from across the field
Plus Two Interactive Half-Day Post-Conference Workshops | Wednesday 11th April 2018
Workshop A: ADCs from early development into first-in-human studiesWorkshop Leader: Peter Bach, Biotechnology Consultant, BioPharmaLogic
08.30 - 12.30
Workshop B: Recombinant Antibodies - structure, function and drug developmentWorkshop Leaders:Dr Mahendra Deonarain, CEO & CSO, Antikor Biopharma Ltd
Prof Kerry Chester, Professor of Molecular Medicine, UCL
13.30 - 17.30
Chairs for 2018:
- Mahendra Deonarain, Chief Executive and Scientific Officer, Antikor Biopharma
- Rakesh Dixit, Vice President and Global Head Biologics Safety Assessment, Medimmune
Key Speakers Include:
- Robert Lyon, Senior Director, Seattle Genetics
- Arnaud Tiberghien, Scientist II, Spirogen
- Alison Betts, Associate Research Fellow, Pfizer
- Thomas Pillow, Senior Scientist, Genentech
- Andreas Pahl, CSO, Heidelberg Pharma
- Carlo Boutton, Director of Technology, Ablynx
Please fill in your name and email to receive the conference agenda of this event.
The agenda is available as PDF under downloads at the right side of the page.
Venue
Copthorne Tara Hotel
Scarsdale Pl, Kensington, W8 5SY
London, UK
Who should attend
Key Job Titles include:
- Research & Development Directors/Managers/Scientists
- Senior Scientists
- Chief Scientific Officers
- Chief Medical Officers
- Heads of Clinical Development
- Heads of Pre-Clinical Development
- Global Presence: Attendees from all over the world attend our events, gain hands on insight from representatives from UK, Europe and USA.
Venue
Copthorne Tara HotelScarsdale Place, Kensington
London, United Kingdom
